Israeli clinical stage biotechnology company Novellus, Ltd., specializing in precision oncology, announced the closure of its Series C funding round in which the company raised $57 million.
The IPO of Graybug Vision, Inc. will take place on September 24, 2020. It is a clinical-stage biopharmaceutical company specializing in the development of transformative medicines for the treatment of diseases of the retina and optic nerve.
The IPO of Prelude Therapeutics will take place on September 24, 2020. It is a biotechnological company that develops medicines that target chromatin function for the treatment of cancer and rare diseases.
Aidoc, which is an Israeli startup that develops artificial intelligence based technologies for radiologists, raised additional $20 million as a part of its Series B round started in April 2019.